Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - linezolid - infusion - 2mg/1ml

Airija - anglų - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - paclitaxel - concentrate for solution for infusion - 6 milligram(s)/millilitre - taxanes - plant alkaloids and other natural products, taxanes - it is indicated for the treatment of patients with carcinoma. see spc for all therapeutic indications

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 340 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; sodium chloride; dimethyl sulfoxide - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of relapsed or refractory large b-cell lymphoma after two or more lines of systemic therapy, including diffuse large b-cell lymphoma (dlbcl) not otherwise specified, primary mediastinal large b-cell lymphoma, high grade b-cell lymphoma, and dlbcl arising from follicular lymphoma. yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - axicabtagene ciloleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - yescarta is a genetically modified autologous immunocellular therapy for the treatment of:large b-cell lymphoma - patients with relapsed or refractory large b-cell lymphoma (lbcl).yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. follicular lymphoma - patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

1,000unit) powder and 20ml solvent for solution for infusion vials (takeda uk ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for infusion - 1000unit

Singapūras - anglų - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - ustekinumab - infusion, solution concentrate - ustekinumab 130mg/vial

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - mannitol - infusion - 200mg/1ml

Singapūras - anglų - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - levetiracetam - infusion, solution concentrate - 500 mg per vial - levetiracetam 500 mg per vial